Adlai Nortye Group Earnings Call Transcripts
Fiscal Year 2026
-
The H1 2027 AN9025 readout is expected to include at least 50 efficacious-dose patients, predominantly with PDAC; differentiation will hinge on efficacy, tolerability and combination potential. AN4035 data are expected in H2 2027, with ~$232 million in H1 2026 cash projected to fund both catalysts and operations through 2028.
-
The event highlighted progress on two lead oncology assets: AN9025, a potent oral pan-RAS(ON) inhibitor in phase I trials with both daily and weekly dosing, and AN4035, a first-in-class ADC targeting CEACAM5. Key clinical data are expected in 2027, supported by a strong cash position.
-
Two RAS-targeted programs are advancing, with AN9025 in phase I and AN4035 ADC entering clinical studies in 2024. Intermittent dosing may widen the therapeutic window, and the ADC platform enables selective tumor targeting and rational combinations, especially in colorectal cancer.